symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
APGE,21.15,0,287642,1071761445,0,18.99-25.54,0.78,"Apogee Therapeutics, Inc.",USD,0001974640,,,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.apogeetherapeutics.com,"Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.",Dr. Michael Thomas Henderson M.D.,Healthcare,US,25,650-394-5230,221 Crescent Street,Waltham,MA,02453,,0,https://financialmodelingprep.com/image-stock/APGE.png,2023-07-14,True,False,True,False,False
